Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 17c

November 5, 2019 7:37 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.63), $0.17 better than the analyst estimate of ($0.80).

“I am pleased with the significant progress we have made in the third quarter across our commercial, regulatory, and clinical initiatives,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “We are preparing for a potential launch of lumateperone in the first quarter of 2020, and continue to advance our clinical programs, including our PDE1 program and our Phase 3 trial evaluating lumateperone as an adjunctive therapy in bipolar depression.”

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, Management Comments

Related Entities

The Children's Investment Fund (TCI), Earnings